USD 1.03
(1.97%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 | 90.37 Million USD | -6.93% |
2023 | 97.1 Million USD | 6.09% |
2022 | 91.53 Million USD | -28.55% |
2021 | 128.1 Million USD | 121.55% |
2020 | 57.82 Million USD | 109.24% |
2019 | 27.63 Million USD | 261.9% |
2018 | 7.63 Million USD | -30.58% |
2017 | 10.99 Million USD | -22.86% |
2016 | 14.25 Million USD | 446.2% |
2015 | 2.61 Million USD | -60.73% |
2014 | 6.64 Million USD | 5414.78% |
2013 | 120.52 Thousand USD | 46.33% |
2012 | 82.36 Thousand USD | 40.96% |
2011 | 58.43 Thousand USD | -29.34% |
2010 | 82.69 Thousand USD | 49.18% |
2009 | 55.43 Thousand USD | 15.21% |
2008 | 48.11 Thousand USD | 17.74% |
2007 | 40.86 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q4 | 90.37 Million USD | -7.86% |
2024 Q3 | 98.08 Million USD | -0.32% |
2024 Q2 | 98.39 Million USD | -2.31% |
2024 Q1 | 100.72 Million USD | 3.72% |
2023 Q3 | 106.3 Million USD | 11.17% |
2023 Q2 | 95.61 Million USD | -0.49% |
2023 Q4 | 97.1 Million USD | -8.65% |
2023 Q1 | 96.09 Million USD | 4.99% |
2023 FY | 97.1 Million USD | 6.09% |
2022 Q1 | 116.22 Million USD | -9.27% |
2022 FY | 91.53 Million USD | -28.55% |
2022 Q4 | 91.53 Million USD | -15.0% |
2022 Q3 | 107.68 Million USD | -8.97% |
2022 Q2 | 118.28 Million USD | 1.77% |
2021 Q4 | 128.1 Million USD | -0.24% |
2021 FY | 128.1 Million USD | 121.55% |
2021 Q1 | 50.2 Million USD | -13.17% |
2021 Q2 | 54.04 Million USD | 7.65% |
2021 Q3 | 128.4 Million USD | 137.57% |
2020 Q2 | 57.38 Million USD | 99.96% |
2020 Q3 | 73.24 Million USD | 27.64% |
2020 FY | 57.82 Million USD | 109.24% |
2020 Q4 | 57.82 Million USD | -21.06% |
2020 Q1 | 28.7 Million USD | 3.86% |
2019 Q1 | 7.85 Million USD | 2.87% |
2019 FY | 27.63 Million USD | 261.9% |
2019 Q3 | 22.3 Million USD | -0.89% |
2019 Q4 | 27.63 Million USD | 23.91% |
2019 Q2 | 22.5 Million USD | 186.47% |
2018 FY | 7.63 Million USD | -30.58% |
2018 Q4 | 7.63 Million USD | -28.13% |
2018 Q2 | 15.82 Million USD | 6.28% |
2018 Q1 | 14.89 Million USD | 35.41% |
2018 Q3 | 10.62 Million USD | -32.88% |
2017 Q3 | 7.39 Million USD | -33.13% |
2017 Q2 | 11.05 Million USD | -15.02% |
2017 FY | 10.99 Million USD | -22.86% |
2017 Q1 | 13.01 Million USD | -8.72% |
2017 Q4 | 10.99 Million USD | 48.73% |
2016 Q2 | 9.15 Million USD | 15.09% |
2016 Q4 | 14.25 Million USD | 222.58% |
2016 FY | 14.25 Million USD | 446.2% |
2016 Q1 | 7.95 Million USD | 204.59% |
2016 Q3 | 4.41 Million USD | -51.7% |
2015 Q4 | 2.61 Million USD | -72.95% |
2015 FY | 2.61 Million USD | -60.73% |
2015 Q3 | 9.65 Million USD | 17368.65% |
2015 Q2 | 55.24 Thousand USD | 9.39% |
2015 Q1 | 50.5 Thousand USD | 1.94% |
2014 Q3 | 153.44 Thousand USD | 15.04% |
2014 Q4 | 49.53 Thousand USD | -67.72% |
2014 Q1 | 120.52 Thousand USD | 4.39% |
2014 FY | 6.64 Million USD | 5414.78% |
2014 Q2 | 133.38 Thousand USD | 10.67% |
2013 Q3 | 107.94 Thousand USD | 14.71% |
2013 Q4 | 115.45 Thousand USD | 6.95% |
2013 FY | 120.52 Thousand USD | 46.33% |
2013 Q1 | 82.36 Thousand USD | 19.45% |
2013 Q2 | 94.1 Thousand USD | 14.25% |
2012 Q3 | 65.74 Thousand USD | -1.06% |
2012 Q2 | 66.44 Thousand USD | 13.71% |
2012 FY | 82.36 Thousand USD | 40.96% |
2012 Q1 | 58.43 Thousand USD | -12.06% |
2012 Q4 | 68.95 Thousand USD | 4.89% |
2011 Q4 | 66.44 Thousand USD | 26.36% |
2011 FY | 58.43 Thousand USD | -29.34% |
2011 Q3 | 52.58 Thousand USD | -43.1% |
2011 Q2 | 92.41 Thousand USD | 11.75% |
2011 Q1 | 82.69 Thousand USD | -1.84% |
2010 Q2 | 61.19 Thousand USD | 10.39% |
2010 Q3 | 67.54 Thousand USD | 10.38% |
2010 FY | 82.69 Thousand USD | 49.18% |
2010 Q4 | 84.24 Thousand USD | 24.73% |
2010 Q1 | 55.43 Thousand USD | 0.1% |
2009 Q1 | 48.11 Thousand USD | 8.55% |
2009 Q4 | 55.38 Thousand USD | 5.51% |
2009 Q3 | 52.48 Thousand USD | 4.69% |
2009 Q2 | 50.13 Thousand USD | 4.2% |
2009 FY | 55.43 Thousand USD | 15.21% |
2008 Q1 | 40.86 Thousand USD | 5.85% |
2008 FY | 48.11 Thousand USD | 17.74% |
2008 Q4 | 44.32 Thousand USD | 10.37% |
2008 Q2 | 43.13 Thousand USD | 5.56% |
2008 Q3 | 40.15 Thousand USD | -6.91% |
2007 Q4 | 38.61 Thousand USD | 0.0% |
2007 FY | 40.86 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Journey Medical Corporation | 56.49 Million USD | -59.966% |
Safety Shot Inc | 3.89 Million USD | -2222.147% |
Bright Green Corporation | 6.43 Million USD | -1303.814% |
Alvotech | 1.88 Billion USD | 95.199% |
Aquestive Therapeutics, Inc. | 163.9 Million USD | 44.859% |
Cosmos Health Inc. | 30.25 Million USD | -198.749% |
Dynavax Technologies Corporation | 375.02 Million USD | 75.9% |
Embecta Corp. | 2.03 Billion USD | 95.561% |
Esperion Therapeutics, Inc. | 660.79 Million USD | 86.323% |
Intra-Cellular Therapies, Inc. | 136.87 Million USD | 33.968% |
Pacira BioSciences, Inc. | 704.25 Million USD | 87.167% |
PainReform Ltd. | 2.69 Million USD | -3258.566% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -1372.067% |
SCYNEXIS, Inc. | 55.45 Million USD | -62.992% |
China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -882.742% |
Alpha Teknova, Inc. | 38.55 Million USD | -134.44% |
ANI Pharmaceuticals, Inc. | 471.67 Million USD | 80.839% |
Collegium Pharmaceutical, Inc. | 947.87 Million USD | 90.465% |
Sunshine Biopharma, Inc. | 6.13 Million USD | -1372.067% |
Procaps Group, S.A. | 462.06 Million USD | 80.44% |
Theratechnologies Inc. | 98.63 Million USD | 8.374% |
Harrow Health, Inc. | 241.75 Million USD | 62.615% |
Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -932.195% |
Biofrontera Inc. | 23.13 Million USD | -290.592% |
DURECT Corporation | 30.4 Million USD | -197.241% |
Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 81.459% |
Cronos Group Inc. | 43.73 Million USD | -106.646% |
OptiNose, Inc. | 194.33 Million USD | 53.493% |
Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 88.943% |
Kala Pharmaceuticals, Inc. | 48.44 Million USD | -86.56% |
RedHill Biopharma Ltd. | 20.97 Million USD | -330.825% |
Organogenesis Holdings Inc. | 181.36 Million USD | 50.167% |
Guardion Health Sciences, Inc. | 3.77 Million USD | -2295.965% |
Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -72.097% |
Radius Health, Inc. | 804.29 Million USD | 88.763% |
Universe Pharmaceuticals INC | 13.75 Million USD | -557.095% |
ProPhase Labs, Inc. | 42.54 Million USD | -112.437% |
Phibro Animal Health Corporation | 725.54 Million USD | 87.543% |
Procaps Group S.A. | 462.06 Million USD | 80.44% |
TherapeuticsMD, Inc. | 14.02 Million USD | -544.551% |
Viatris Inc. | 27.21 Billion USD | 99.668% |
Rockwell Medical, Inc. | 30.88 Million USD | -192.659% |
SIGA Technologies, Inc. | 57.97 Million USD | -55.887% |
Tilray Brands, Inc. | 892.11 Million USD | 89.869% |
Lifecore Biomedical, Inc. | 219.8 Million USD | 58.881% |
Shineco, Inc. | 47.6 Million USD | -89.865% |
PetIQ, Inc. | 645.22 Million USD | 85.993% |
Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -41072.692% |
Incannex Healthcare Limited | 5.83 Million USD | -1450.24% |
Neurocrine Biosciences, Inc. | 1.01 Billion USD | 91.134% |
Alimera Sciences, Inc. | 107.35 Million USD | 15.812% |
Silver Spike Investment Corp. | 3 Million USD | -2902.793% |
Assertio Holdings, Inc. | 148.41 Million USD | 39.104% |
Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -4666.913% |
Petros Pharmaceuticals, Inc. | 21.31 Million USD | -324.001% |
Clever Leaves Holdings Inc. | 7.02 Million USD | -1186.351% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -964.468% |
Avadel Pharmaceuticals plc | 173.38 Million USD | 47.874% |
Hempacco Co., Inc. | 18.82 Million USD | -380.167% |
Talphera, Inc. | 6.29 Million USD | -1336.868% |
Alvotech | 1.88 Billion USD | 95.199% |
Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 47.637% |
Lantheus Holdings, Inc. | 835.25 Million USD | 89.179% |
Currenc Group, Inc. | 177.67 Million USD | 49.133% |
Kamada Ltd. | 109.96 Million USD | 17.814% |
Indivior PLC | 1.95 Billion USD | 95.368% |
Evoke Pharma, Inc. | 9.64 Million USD | -836.756% |
Flora Growth Corp. | 17.22 Million USD | -424.788% |
Cyclo Therapeutics, Inc. | 8.49 Million USD | -964.468% |
Evolus, Inc. | 209.68 Million USD | 56.898% |
HUTCHMED (China) Limited | 536.38 Million USD | 83.15% |
Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 89.653% |
Akanda Corp. | 12.66 Million USD | -613.393% |